<?xml version="1.0" encoding="UTF-8"?>
<p>The natural history of COVID-19 and some lessons from infections with the previous SARS coronavirus (SARS-CoV-1) and the more distantly related MERS-CoV, including animal model studies, do raise some concerns about NAb-based therapies and vaccines, warranting careful surveillance by clinicians during human trials. Furthermore, certain approaches may minimize risks while preserving the benefits of passive immunization for curing COVID-19.</p>
